Trial identifies subset of breast cancer patients most likely to benefit from Neratinib
The I-SPY 2 trial identified a neo-adjuvant regimen containing the investigational drug neratinib and standard chemotherapy to be beneficial for hormone receptor (HR)-negative, HER2-positive primary (non-metastatic) breast ...
Apr 8, 2014
0
0